Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
Aquestive Therapeutics, Inc. (AQST)
Sector: Healthcare; Industry: Biotechnology

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-02-10 Schobel Alexander Mark Chief Innovation/Tech Officer Sell 35,000 $6.75 $236,250 No
2021-02-08 Schobel Alexander Mark Chief Innovation/Tech Officer Sell 40,792 $6.50 $265,148 No
2020-08-18 Maxwell John T. SVP-Chief Financial Officer Sell 3,000 $8.00 $24,000 No
2020-06-04 Kendall Keith J CEO and President Sell 50,000 $5.11 $255,310 No
2020-05-08 Schobel Alexander Mark Chief Innovation/Tech Officer Sell 40,000 $5.00 $200,000 No
2020-04-27 Schobel Alexander Mark Chief Innovation/Tech Officer Sell 80,000 $3.85 $308,000 No
2020-04-29 Schobel Alexander Mark Chief Innovation/Tech Officer Sell 40,000 $4.50 $180,000 No
2020-03-16 BRAENDER LORI J SVP, General Counsel Buy 14,000 $1.54 $21,624 Yes
2020-03-16 Boyd Peter E. SVP-Bus. Process & Info. Tech. Buy 2,000 $1.50 $3,000 Yes
2019-08-27 Barber Daniel SVP-Chief Operating Officer Buy 2,000 $3.99 $7,980 No
2019-08-21 Scibetta James S Director Buy 22,971 $3.79 $86,977 No
2019-08-14 Kendall Keith J CEO and President Buy 8,000 $3.87 $30,987 No
2019-08-09 Wood Theresa SVP-HR and Org. Development Buy 1,000 $3.99 $3,990 No
2019-08-09 BRAENDER LORI J SVP, General Counsel Buy 10,000 $4.07 $40,747 No
2019-08-12 Boyd Peter E. SVP-Bus. Process & Info. Tech. Buy 600 $3.81 $2,286 No
2018-12-10 Schobel Alexander Mark Chief Innovation/Tech Officer Buy 1,000 $7.78 $7,780 No
2018-12-06 Schobel Alexander Mark Chief Innovation/Tech Officer Buy 2,000 $8.69 $17,380 No
2018-12-10 Barber Daniel SVP-Chief Strategy/Dev Officer Buy 1,000 $8.00 $8,000 No
2018-12-06 Maxwell John T. SVP-Chief Financial Officer Buy 5,000 $8.87 $44,350 No
2018-11-21 Marshall Ken W. Commercial Leader Buy 1,445 $10.15 $14,667 No
2018-11-27 BRAENDER LORI J General Counsel Buy 1,000 $10.57 $10,570 No
2018-11-27 Kendall Keith J CEO and President Buy 1,000 $9.87 $9,870 No
2018-11-26 Wood Theresa SVP-HR and Org. Development Buy 500 $10.34 $5,170 No
2018-11-21 Schobel Alexander Mark Chief Innovation/Tech Officer Buy 1,000 $10.25 $10,250 No
2018-11-21 Maxwell John T. SVP-Chief Financial Officer Buy 10,000 $9.80 $98,000 No
2018-11-23 Kendall Keith J CEO and President Buy 7,950 $10.10 $80,325 No
2018-11-21 Boyd Peter E. SVP-Operations/Value Delivery Buy 200 $9.98 $1,996 No
2018-07-24 BRATTON DOUGLAS K 10%-Owner, Director Buy 165,000 $15.00 $2,475,000 No

Insider Smart

MGM Resorts International (MGM) - If we were to pick one of the easy trade from the crash, it has to be MGM, checkout the impressive insider buying after crash. Do you really need more confidence to pull the trigger? That's the mental edge you need to work against fear.